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Abstract
Background: The human polyomavirus BK (BKV) infects humans worldwide and establishes a persistent infection in the
kidney. The BK virus genome encodes three regulatory proteins, large and small tumor-antigen and the agnoprotein, as well
as the capsid proteins VP1 to VP3. Agnoprotein is conserved among BKV, JC virus (JCV) and SV40, and agnoprotein-deficient
mutants reveal reduced viral propagation. Studies with JCV and SV40 indicate that their agnoproteins may be involved in
transcription, replication and/or nuclear and cellular release of the virus. However, the exact function(s) of agnoprotein of BK
virus remains elusive.
Principal Findings: As a strategy of exploring the functions of BKV agnoprotein, we decided to look for cellular interaction
partners for the viral protein. Several partners were identified by yeast two-hybrid assay, among them a-SNAP which is
involved in disassembly of vesicles during secretion. BKV agnoprotein and a-SNAP were found to partially co-localize in cells,
and a complex consisting of agnoprotein and a-SNAP could be co-immunoprecipitated from cells ectopically expressing the
proteins as well as from BKV-transfected cells. The N-terminal part of the agnoprotein was sufficient for the interaction with
a-SNAP. Finally, we could show that BKV agnoprotein negatively interferes with secretion of VSVG-EGFP reporter suggesting
that agnoprotein may modulate exocytosis.
Conclusions: We have identified the first cellular interaction partner for BKV agnoprotein. The most N-terminal part of BKV
agnoprotein is involved in the interaction with a-SNAP. Presence of BKV agnoprotein negatively interferes with secretion of
VSVG-EGFP reporter.
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Introduction
Polyomaviridae are non-enveloped viruses containing a circular
double stranded DNA genome of approximately 5,000 base pairs.
Polyomaviruses infect several species, including birds, rodents,
bovine, monkeys and human [1]. So far, eleven polyomaviruses
have been found in humans. The first two were discovered in
1971, and named BK virus and JC virus after the initials of the
patients from which they were originally isolated [2]. Two monkey
polyomaviruses, lymphotropic polyomavirus (LPV) and simian
virus 40 (SV40) also circulate among humans as indicated by the
presence of antibodies against these viruses [3]. Moreover, in
human leukoencephalopathy cases, SV40 and LPV DNA were
detected in tonsils and in peripheral blood, respectively [4,5]. A
few years ago, two novel polyomaviruses, designated KI virus and
WU virus, were found in human nasopharyngeal aspirates [6,7],
while a third, not previously described polyomavirus in Merkel cell
carcinoma was isolated and accordingly named Merkel cell
polyomavirus [8]. Last year, another three new human poly-
omaviruses were reported. Two of them were isolated from skin
swabs, and referred to as human polyomavirus-6 (HPyV6) and -7
(HPyV7) [9]. The third virus was identified in spicules of
trichodysplasia spinulosa (TS) and was named trichodysplasia
spinulosa-associated polyomavirus (TSV) [10]. Finally, this year
another human polyomavirus was detected in a kidney transplant
patient, and named HPyV9 [11]. Given the rapid discovery of
more and more of these viruses, it becomes very important to
understand how the individual viral proteins interfere with host
cell functions.
The most studied polyomaviruses are JCV, BKV and SV40.
The primary infection of the two former typically occurs in
childhood. Both viruses then establish a latent infection in kidney
and peripheral blood in 35–85% of the population worldwide
[1]. Asymptomatic reactivation of BKV may occur in 5% of the
healthy individuals and during pregnancy. Although apparently
harmless in immunocompetent hosts, BKV and JCV can cause
diseases in immunocompromised individuals. BKV is a significant
pathogen in kidney transplant patients, causing polyomavirus-
associated nephropathy, which may result in renal allograft loss,
while in bone-marrow recipients, BKV can cause hemorrhagic
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cystitis [12,13]. JCV is the etiological agent of progressive
multifocal leukoencephalopathy [14].
Phylogenetic studies have shown that BKV, JCV and SV40 are
more closely related compared to the other human polyomaviruses
[8,15]. The polyomavirus genome of SV40, JCV and BKV is
divided into three functional parts consisting of an early and a late
gene region separated by a non-coding control region (NCCR).
The NCCR contains the origin of replication as well as the
promoter-enhancer sequences for the early and late genes. The
early region encodes the regulatory proteins large tumor-antigen
(LT-ag) and small tumor-antigen (st-ag), as well as other truncated
LT-ag variants. The late region encodes the structural capsid
proteins VP1, VP2 and VP3, and a regulatory protein named
agnoprotein (reviewed in [16]). In addition, SV40 encodes a very
late protein named VP4, which is involved in cell lysis [17]. VP4
corresponding open reading frames are present in the genomes of
BKV and JCV, but the expression of this protein remains to be
demonstrated.
The agnoprotein is a basic protein of 8 kD and its primary
sequence is conserved among SV40, JCV and BKV especially at
the N-terminal part of the protein [2]. The protein is
phosphorylated in vivo [18]. Polyomavirus propagation studies
with mutants in which phosphorylation sites were replaced by non-
phosphorylatable alanines have been performed with BK and JC
virus. JC virus expressing agnoprotein T21A, S7A/S11A/T21A
or S7A/S11A is unable to propagate in SVG-A cells [19]. BK
virus expressing agnoprotein S11A propagates in Vero and
HUVECC cells, although less efficiently than wild-type [20].
Studies with wild-type and agnoprotein-deficient mutants of SV40,
JCV and BKV revealed that the viruses which do not express
agnoprotein propagate less efficiently but remain infectious
[19–22].
Agnoprotein mainly resides in the cytoplasm, but a minor
fraction can also locate to the nucleus in SV40, JCV and BKV
infected cells [18,20], suggesting functions in both cellular
compartments. Previous studies showed the involvement of
agnoprotein in nuclear egress, regulation of gene expression or/
and replication, virion assembly or/and maturation and viral
release [18,22–24]. Recently, BKV agnoprotein was found to co-
localize with lipid droplets, but the biological relevance of this
finding is unclear [25]. Several cellular interaction partners have
been identified for JCV agnoprotein, as reviewed in [2] and
proteins of 50, 75 and 100 kD have been shown to precipitate with
BKV agnoprotein [26]. However, the identity of these proteins
and the biological functions of most of these interactions remain
elusive.
a-soluble N-ethylmaleimide-sensitive fusion (NSF) attachment
protein (a-SNAP) is a ubiquitous and indispensable component of
the membrane fusion machinery. The plasma membrane and
membrane-enclosed organelles like the endoplasmic reticulum
(ER), Golgi apparatus and transport vesicles contain specialized
membrane receptors known as soluble N-ethylmaleimide-sensitive
factor attachment protein receptor (SNARE). During the fusion of
two membranes, the SNAREs of opposing membranes interact in
trans and undergo a conformational change by which they bring
the two membranes in very close proximity. It is assumed that this
proximity promotes fusion of the lipid bilayer and content mixing.
After the fusion event, the SNARE complexes (now in cis) have to
be disassembled in order to be ready to undergo another round of
fusion. Therefore, a-SNAP binds cis-SNARE complexes, recruit-
ing and stimulating the ATPase N-ethylmaleimide-sensitive factor
(NSF) that disassembles cis-SNARE complexes [27,28].
In an effort to improve our understanding of the role of
agnoprotein in BKV’s life cycle, we performed a yeast two-hybrid
assay with BKV agnoprotein as bait and isolated putative cellular
interaction partners, one of which was a-SNAP. We confirmed the
interaction between BKV agnoprotein and a-SNAP both in vitro
and in vivo. Moreover, we show that the N-terminal 38 amino acids
of BKV agnoprotein are sufficient for this interaction. Finally, we
provide evidence that the presence of ectopically expressed
agnoprotein negatively interferes with secretion of VSVG-EGFP-
reporter. We propose that agnoprotein modulates exocytosis.
Materials and Methods
Materials
Thrombin was obtained from Amersham Biosciences. Fetal
Bovine Serum (FBS) and cell culture medium were obtained from
Invitrogen (Carlsbad, CA, USA). CDP-star and MagicMarkTM
XP Western Protein Standard (CA, USA) and Invitrogen (Oslo,
Norway), respectively. Antibodies against agnoprotein were
described previously [26]. Antibodies against a-SNAP (FL-295),
Hsp27 (H-77, sc-9012) and GST (Z-5; sc-459) were from Santa
Cruz, while the antibody for actin was from Sigma Aldrich. SV40
LT-ag AB-2 was from Calbiochem, while antiserum for BKV LT-
ag and VP1 has been described previously [29,30]. Alkaline
phosphatase conjugated anti-rabbit antibody was purchased
from DAKO (Denmark). Fluorophore-conjugated antibodies
Alexa Fluor 488 and 568 were obtained from Invitrogen Life
Technologies (Oslo, Norway).
The agnoprotein peptides 1–37 (MVLRQL SRQASV-
KVGKTWTGTKKRAQRIFIFILELLL), 15–45 (GKTWTGT-
KKRAQRIFIFILE LLLEFCRGED) and 38–66 (EFCRGED-
SVDGKNKSTTALPAVKDSVKDS) were synthesized by Gene
Cust (Luxembourg).
Cell lines
HEK293 (ECACC catalog number 85120602) was purchased
from European Collection of Cell Cultures, while Vero (ATCC
catalog number CCL81) and U2OS cells (ATCC catalog number
HTB-96) were purchased from American Type Culture Collec-
tion. All the cells were maintained in Dulbecco’s modified Eagle’s
medium supplemented with 10% (v/v) fetal bovine serum,
penicillin (100 units/ml), and 100 mg/ml streptomycin (Invitrogen)
in a CO2 incubator (5% CO2) at 37uC.
Plasmid constructs
The empty expression vectors pRcCMV, pCMV and pGEX-
4T-1 were purchased from Invitrogen, Clontech and GE
Healthcare, respectively. pRcCMV-agno and pGST-agno have
been described previously [20,26]. pCMV5-a-SNAP was pur-
chased from Origen (Rockville, USA), while pET11d-His-a-SNAP
was provided by Dr. Mitsuo Tagoya [31], and the VSVG-EGFP ts
construct [32] was purchased from Addgene (Cambridge, USA).
pCMV2-Flag-Hsp27 was kindly provided by Dr. Kuy-Jin Park
[33]. pGST-agno-stop38 was created by introducing a stop codon
by site-specific mutagenesis using a complementary primer set of
59-gag ctt ttg ctg taa ttt tgt aga ggt g-39 (only one strand shown).
The mutation was confirmed by sequencing, and the obtained
construct was used as template in a new round of site-specific
mutagenesis with the complementary primer set of 59-ctt ttg ctg
taa tag tga tga ggt gaa gac-39 (only one strand shown) resulting in
additional three successive stop codons. Finally, all mutations were
verified by sequencing.
Protein purifications
GST fusion proteins were purified from Escherichia coli BL21
extracts using glutathione-agarose beads, and the agnoprotein
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moiety was enzymatically cleaved from the GST-beads with
thrombin according to the instructions of the manufacturer. His-
tagged proteins were purified from Escherichia coli BL21 or
BL21(DE3) according to the instructions of the manufacturer.
Preparation of viral genome and transient transfection
Transfection studies with expression plasmids in HEK293 and
Vero cells were done using Lipofectamine 2000 (Invitrogen)
according to the instructions of the manufacturer. BKV DNA used
in transfection was prepared from the plasmid pBK34-2 (ATCC
cat. no. 45025) as follows. The plasmid was digested with BamHI/
BglII to release the BKV genome which is cloned in the BamHI
site of pB322, while BglII digested pBr322 in several smaller
fragments. The linearized DNA was purified and relegated with
T4-ligase and used for transfection of U2OS cells.
Immunoprecipitations
Confluent 10 cm dishes with HEK293 cells were transfected
with appropriate expression plasmids. The cells were harvested
and the proteins immunoprecipitated as previously described [34].
For the in vitro co-immunoprecipitations, purified protein(s) were
added to 200 ml precipitation buffer containing 50 mM Tris-HCl,
pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM DTT and complete
protease inhibitor mixture (Roche Diagnostic) and incubated at
room temperature for 10 minutes. The samples were precleared
by addition of 50 ml 50% protein G-Sepharose slurry followed by
30 minutes incubation at room temperature. The supernatant was
then incubated with the appropriate antibody for 1 hour at 4uC,
followed by precipitation of the complexes with protein G-
sepharose. The immune complexes were washed three times with
an extensive volume of ice cold precipitation buffer (see above),
and subsequently subjected to SDS PAGE followed by etiher
immunoblot analysis Coomassie blue G staining.
GST-pulldown
36106 HEK293 cells were washed twice with PBS, and
harvested in 3 ml ice-cold PBS with 1% Triton-X100 (PBST).
The GST-pulldown was performed as described previously [35].
Briefly, the cell lysate was precleared with 25 mg GST and 50 ml of
50% slurry of glutathione-agarose beads for 2 hours at 4uC. An
input control was taken, and the cell lysate was divided into three
tubes and 10 mg of GST, GST-agnoprotein or GST-agnoprotein-
stop38 were added. The GST proteins were recovered after
addition of glutathione beads and washed extensively in PBST.
The proteins were eluted from the beads by addition of 20 ml
loading buffer (16LDS-buffer with 100 mM DTT) followed by
10 minutes incubation at 70uC. The GST proteins were
subsequently subjected to immunoblot analysis.
Immunofluorescence analysis
Cells were rinsed twice with phosphate-buffered saline (PBS)
and fixed for 10 minutes with 4% formaldehyde. Next, the cells
were washed twice with PBS and permeabilized with PBS
containing 0.1% Triton X-100 for 5 minutes. The cells were
thereafter washed twice with cold PBS prior to blocking for
30 minutes with 3% goat serum in PBS at room temperature.
Finally immunostaining was performed, i.e. PBS with 1% goat
serum and primary antibodies (rabbit antiserum against agnopro-
tein (1:600 dilution) and/or mouse antibody against a- SNAP
(1:100) were added to the cells, and incubated at 37uC for
30 minutes. After seven washes with PBS, the cells were stained
with secondary rabbit antibody conjugated to Alexa Fluor 488
(green) (1:500) or secondary mouse monoclonal antibody conju-
gated to Alexa Fluor 568 (red) (1:500) in 1% goat serum in PBS for
30 minutes at room temperature. After seven new washes with
PBS, the cells were stained with DRAQ5 (1:1000) for 5 minutes at
room temperature. The cells were finally washed twice in PBS,
and examined using a confocal laser-scanning Zeiss LSM 510
META and a Leica SP5 microscope.
Immunoblot analysis
Immunoblot analyses were performed on cell extracts as
described previously [20].
Yeast two-hybrid screen
A yeast two-hybrid service was ordered from www.panbionet.
com. Briefly, the BKV agnoprotein gene was cloned in frame with
the coding sequence of the DNA binding domain of GAL4
(GAL4DB) in pGBKT vector. GAL4-BKV-agnoprotein was then
used as bait in a human kidney cDNA library and a human
thymus cDNA library in the yeast strain PBN204, which has
ADE2, URA3 and lacZ genes as reporters. The transformants were
spread on selection media (SD-LWU) where the selection was
based on the interaction between bait and prey. Thereafter, the
yeast colonies on uracil deficient media were analyzed for other
reporter expression (lacZ and ADE2) that is under the control of a
GAL4 promoter. This approach yielded a total of 6 prey
candidates, which showed agnoprotein-dependent reporter gene
expression.
Results
BKV agnoprotein and a-SNAP partly co-localize in
mammalian cells
The function(s) of BKV agnoprotein remains incompletely
understood. In order to explore the role of agnoprotein, a yeast
two-hybrid screen with BKV agnoprotein as bait against human
kidney and thymus cDNA libraries was performed. The two
screens yielded a total of 6 putative interaction partners for BKV
agnoprotein. One of the interaction partners was found in both
libraries, while the others were found in only one of the libraries.
Among the interaction partners identified in the human kidney
library was a-soluble N-ethylmaleimide-sensitive fusion (NSF)
attachment protein (a-SNAP).
If the proteins would be able to interact in vivo, they should at
least have partly overlapping localization within mammalian cells.
Therefore, we first addressed the localization of BKV agnoprotein
and a-SNAP in mammalian cells. Thereto, Vero cells were
transfected with an expression plasmid encoding BKV agnopro-
tein and immunostained with antibodies against BKV agnoprotein
and a-SNAP. The nucleus was visualized by DRAQ5-staining.
BKV agnoprotein and the endogenous a-SNAP localize diffusely
throughout the cytoplasm. Some common areas are neither
stained by antibodies against agnoprotein nor a-SNAP. Despite
the rather diffuse staining, a partial overlap of the signals of
agnoprotein and a-SNAP was observed (Figure 1A and results
not shown). In order to corroborate this result, we ectopically
expressed both BKV agnoprotein and a-SNAP in Vero cells.
When both proteins were over-expressed within the cells, BKV
agnoprotein localized predominantly perinuclear and throughout
the cytoplasm (Figure 1B, figure S1 and results not shown).
Staining against a-SNAP revealed again a partly similar pattern as
cells stained against BKV agnoprotein, suggesting partial co-
localization (Figure 1B, and results not shown). These results
demonstrate that the two proteins can localize to the same area
within the eukaryotic cell suggesting that a physical interaction
may occur in vivo.
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BKV agnoprotein interacts specifically and directly with
a-SNAP
In order to evaluate whether BKV agnoprotein interacts with a-
SNAP in mammalian cells, HEK293 cells were transfected with an
expression plasmids encoding BKV agnoprotein and/or a-SNAP
or the empty vector. Using antibodies against BKV agnoprotein
and a-SNAP, we performed reciprocal co-immunoprecipitations
and detected subsequent precipitates by immunoblot. Ectopically
expressed a-SNAP was successfully precipitated by BKV agno-
protein (Figure 2A, left panel, upper section, lane 5), while a-
SNAP antibodies could co-immunoprecipitate BKV agnoprotein
(Figure 2A, right panel, upper section, lane 5). As an additional
control for the specificity of the BKV agnoprotein- a-SNAP
interaction, we chose to include a control where we over-expressed
Hsp27 and either BKV agnoprotein or a-SNAP prior to reciprocal
co-immunoprecipitation. As seen in the lower section, both panels
in Figure 2A, ectopically expressed Hsp27 is detected in the input
controls, but is not co-immunoprecipitated with neither BKV
agnoprotein nor a-SNAP (Figure 2A, lower section, both panels).
Next, we asked whether this interaction would also occur under
physiological conditions during viral BKV propagation. Because
BKV can persistently infect U2OS cells [36] and the transfection
efficiency of these cells is 30–40%, U2OS cells were chosen for the
experiment. Cells were transfected with either the complete BKV
genome or the empty vector pBr322. The cells that are transfected
with BKV genome will express viral proteins. Time-course
experiments had shown that BKV agnoprotein expression is
clearly detectable 48 hours after transfection (results not shown),
and the cells were therefore harvested at this time point.
Immunoprecipitations were performed using anti-agnoprotein
antibodies, and the precipitated proteins were separated by SDS
PAGE followed by immunoblotting with antibodies against a-
SNAP. We detected endogenous a-SNAP in the cell lysates from
both BKV- or pBR322-transfected U2OS cells (Figure 2B, lanes 1
and 2). Similarly, BKV- but not pBR322-transfected U2OS cells
expressed agnoprotein (Figure 2B, lanes 1 and 2). The antibody
against BKV agnoprotein precipitated agnoprotein and a-SNAP
in BKV-transfected but not in pBr322-transfected U2OS cells
(Figure 2B, lanes 3 and 4). Considering that approximately 30–
40% of the cells become transfected with BKV genome and
expresses BKV agnoprotein, and the low level of endogenous a-
SNAP in these cells, complexes of both proteins could still be
detected by co-immunoprecipitation. This suggests that a-SNAP
and BKV agnoprotein can interact at physiological concentrations
during viral infection.
One limitation with co-immunoprecipitations - or yeast two-hybrid
experiments - is that the interaction might not be direct, but is
mediated via other protein(s) that are in the precipitated complex. To
verify a direct interaction between BKV agnoprotein and a-SNAP,
we purified BKV agnoprotein and His-tagged a-SNAP protein, and
incubated the proteins together. Then reciprocal in vitro co-
immunoprecipitation experiments were performed. The immuno-
precipitated a-SNAP could clearly co-precipitate BKV agnoprotein
(Figure 2C, left panel). Similarly, BKV agnoprotein could co-
immunoprecipitate a-SNAP (Figure 2C, right panel).
In conclusion, BKV agnoprotein can interact directly with a-
SNAP both in vitro and in vivo with ectopically or endogenously
expressed proteins.
The N-terminal part of BKV agnoprotein can interact with
a-SNAP
In order to evaluate which region of agnoprotein is involved in
the interaction with a-SNAP, peptides consisting of various parts
of BKV agnoprotein were synthesized. Peptide 1 consists of amino
acids 1–37, while peptide 2 and 3 encompass amino acids 15–45
and 38–66, respectively. Our polyclonal agnoprotein antibody
seems to detect the various peptides with different efficiency
(results not shown). For the in vitro binding experiments, we
therefore incubated 25 mM peptides with 3 mM a-SNAP, and
precipitated protein-peptide complexes using antibodies against a-
SNAP. The precipitated complexes were separated on SDS PAGE
followed by Coomassie blue staining (Figure 3A). Agnopeptide 1–
37 and agnopeptide 15–45 are seen as clear bands of
approximately equal strength in the input control. Unfortunately,
peptide 38–66 was not detected on Coomassie blue, Ponceau S or
silver-stained gels (Figure 3A and results not shown), however the
peptide’s integrity is confirmed by immunoblot and HPLC (Figure
S2 and results not shown). Both peptides 1–37 and 15–45 co-
immunoprecipitated with a-SNAP, although the former did so
more potently (Figure 3A). In order to evaluate whether the
peptide 38–66 also could interact with a-SNAP, we decided to
perform a competitive in vitro co-immunoprecipitation. To this
end, a-SNAP and peptide 1–37 were mixed in the presence of
increasing concentrations of peptide 38–66. If the latter peptide
interacts with a-SNAP, then the interaction between a-SNAP and
peptide 1–37 should be reduced in the presence of increasing levels
of peptide 38–66. As seen in Figure 3B, increasing levels of peptide
38–66 do not influence the ability of peptide 1–37 to co-
immunoprecipitate with a-SNAP, suggesting that the C-terminal
part of agnoprotein is not involved in the interaction with a-
SNAP. Next, we decided to perform a similar in vitro co-
immunoprecipitation using peptide 1–37 and increasing concen-
trations of 15–45 or 1–37 as a control. Peptide 1–37 and
increasing amount of peptide 15–45 or 1–37 are clearly seen in the
input controls (Figure 3C, lane 2–8). The antibodies against a-
SNAP could efficiently co-immunoprecipitate peptides from the
mixture containing peptide 1–37 and increasing level of peptide
15–45, however, the level of co-immunoprecipitated peptides do
not correlate with the increase in peptide 15–45 concentration
(Figure 3C, lane 11–13). In contrast, the level co-immunoprecip-
itated peptide 1–37 correlated well with the increasing amount of
peptide 1–37 (Figure 3C, lane 14–16). The lack of correlation of
co-immunopreciptitated 15–45 peptide with increasing concen-
tration of the peptide, may suggest that 1–37 peptide binds a-
SNAP. This is in agreement with the experiment where a-SNAP
pulled down more 1–37 peptide compared to 15–45 peptide
(Figure 3A). This finding suggests that the 1–15 area of BKV
agnoprotein is of particular importance in the interaction to a-
SNAP.
Figure 1. BKV agnoprotein and a-SNAP partly co-localize in Vero cells. (A) Vero cells were transfected with an expression plasmid encoding
BKV agnoprotein (200 ng). The cells were fixed with paraformaldehyde and immunostained with polyclonal rabbit antibodies against BKV
agnoprotein and monoclonal mouse antibodies against endogenous a-SNAP. The primary antibodies were detected by addition of mouse Alexa-568-
coupled secondary antibody (red) and rabbit Alexa488-coupled antibody (green), and the cells were evaluated by confocal microscopy. The cell
nuclei were visualized by DRAQ5 staining. The middle and lower panel is an enlargement of a cell shown in upper panel. (B) Vero cells were co-
transfected with expression plasmids encoding BKV agnoprotein (200 ng) and a-SNAP (200 ng). The cells were fixed and stained as described in A.
The middle and lower panel is an enlargement of the cell shown in upper panel.
doi:10.1371/journal.pone.0024489.g001
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Figure 2. BKV agnoprotein specifically interacts with a-SNAP. (A) HEK cells were transfected with 8 mg of expression plasmids encoding BKV
agnoprotein, a-SNAP and Hsp27, or 8 mg of the empty vector pCMV5 (left panel), or 8 mg of expression plasmids encoding a-SNAP, BKV agnoprotein
and Hsp27 or 8 mg of the empty vector pRcCMV (right panel). Whole cell extract was immunoprecipitated with anti-agnoprotein and anti-a-SNAP
antibodies, respectively. The precipitated proteins were separated by SDS PAGE followed by western blot. The immunoprecipitated proteins were
detected using anti-agnoprotein (left panel, middle section) and anti- a-SNAP antibodies (right panel, middle section), respectively. The co-
immunoprecipitated proteins were detected with antibodies against a-SNAP and Hsp27 (left panel, upper and lower section) or agnoprotein and
Hsp27 (right panel, upper and lower section), respectively. (B) U2OS cells were seeded into two 10 cm dishes and transfected with 8 mg purified BKV
genome or pBr322. Cell lysates were prepared 48 hours post transfection and agnoprotein was immunoprecipitated. The immunoprecipitated
complexes were separated on SDS PAGE and immunoblotted with antibodies against BKV agnoprotein (lower panel) and antibodies against a-SNAP
(upper panel). (C) Purified His-a-SNAP (0.15 mM) or BKV agnoprotein (0.68 mM) were left untreated or supplied with purified 0.68 mM BKV agnoprotein
or 0.15 mM a-SNAP, respectively, and immunoprecipitated with antibodies against a-SNAP or BKV agnoprotein, respectively (lower panel, both
sections). The immunocomplexes were separated by SDS PAGE, and the co-immunoprecipitated proteins were assayed by immunoblotting with
antibodies against agnoprotein or a-SNAP, respectively (top panel, both sections).
doi:10.1371/journal.pone.0024489.g002
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As another approach to evaluate the involvement of the N-
terminal part of BKV agnoprotein in the interaction with a-
SNAP, we decided to generate a C-terminal truncated variant of
agnoprotein by introducing four stop codons starting at amino
acid 38 of BKV agnoprotein. Purified GST, GST-agnoprotein
and GST-agnoprotein-stop38 were then evaluated for their ability
to pull down endogenous a-SNAP from HEK293. The loading of
GST fusion proteins was evaluated by GST-antibodies (Figure 3D,
Figure 3. The N-terminal 38 amino acids of BKV agnoprotein are predominantly required for the interaction with a-SNAP. (A) Purified
His-a-SNAP (3 mM) was left untreated or supplied with peptide 1–37 (25 mM), peptide 15–45 (25 mM) or peptide 38–66 (25 mM). Antibodies against a-
SNAP were added, and the immunocomplexes were separated by SDS PAGE and stained with Coomassie blue. (B) Purified His-a-SNAP (750 nM) was
left untreated or supplied with 6.25 mM peptide 1–37 and ratios 1:0, 1:1, 1:5 and 1:10 of peptide 38–66. a-SNAP was immunoprecipitated by use of
anti-a-SNAP antibodies, and the obtained immunocomplexes were separated by SDS PAGE and stained with Coomassie blue. (C) Purified His-a-SNAP
(750 nM) was left untreated or supplied with 6.25 mM peptide 1–37 and ratios 1:0, 1:1, 1:5 and 1:10 of the peptides 15–45 or peptide 1–37. a-SNAP
was immunoprecipitated by use of anti-a-SNAP antibodies, and the obtained immunocomplexes were separated by SDS PAGE and stained with
Coomassie blue. (D) Proteins (10 mg GST, GST-agnoprotein or GST-agnoprotein-stop38) expressed and purified from bacteria were used to pull down
endogenous a-SNAP from HEK293 cells. The level of a-SNAP which was pulled down was evaluated by immunoblot using antibodies against a-SNAP
(upper panel). In order to evaluate the level of GST proteins, the membrane was stripped and reprobed with antibodies against GST (lower panel).
doi:10.1371/journal.pone.0024489.g003
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lower panel). GST is seen in all the GST-pulldown experiments,
and also slightly in the input control as expected (see Materials and
Methods). The level of GST-agnoprotein-stop38 is slightly lower
than GST-agnoprotein. Still, both GST-agnoprotein and GST-
agnoprotein-stop38 pulled down endogenous a-SNAP from the
cell lysate. No a-SNAP was detected when GST was used as bait,
confirming the involvement of BKV agnoprotein in the pulldown
(Figure 3D, upper panel).
In summary, these results strongly suggest that the conserved N-
terminus of BKV agnoprotein is predominantly involved in the
binding of a-SNAP.
BKV agnoprotein negatively influences the secretion of
VSVG-EGFP
a-SNAP is involved in disassembly of cis-SNARE complexes
after membrane fusion along the secretory pathway [28]. A
marker that is commonly used to study the constitutive secretory
pathway is the Vesicular stomatitis virus glycoprotein ts045 tagged
with green fluorescent protein (VSVG-EGFP) [32]. At restrictive
temperature, i.e. 40uC, VSVG-EGFP adopts a reversible abnor-
mally folded structure, resulting in its retention in the ER.
Transfer to the permissive temperature of 32uC, allows the protein
to fold correctly and to exit the ER and travel through the Golgi
apparatus to the plasma membrane [32].
As we typically obtained transfection efficiency of 80–90% in
HEK293 cells, we chose this cell line to investigate the transport of
VSVG-EGFP in the absence or presence of BKV agnoprotein.
HEK293 cells were transfected with expression plasmids encoding
VSVG-EGFP and BKV agnoprotein or pRcCMV and incubated
at 40uC over night. The next day, cells were fixed immediately
(t = 0) and immunostained for BKV agnoprotein, while the rest of
the cells were transferred to 32uC, captured by fixation and
immunostained at various time intervals (t = 15 min, t = 1 h,
t = 3 h and t = 5 h). For each condition, the localization of
VSVG-EGFP in the cells was evaluated by confocal microscopy
for which at least 20 cells were scored per condition to clearly
establish the respective VSVG-EGFP localization. At t = 0,
VSVG-EGPF was trapped within the cell as expected in all cells
(Figure 4A). Similar patterns were also found at t = 15 minutes and
after 1 hour in cells in presence or absence of BKV agnoprotein
(Figure 4A). After 3 and 5 hours, the cells without BKV
agnoprotein expression lack the concentrated VSVG-EGFP within
the cell, and more fluorescence appeared at the plasma membrane
(Figure 4A and B). In contrast, the VSVG-EGFP remained
trapped within the cells expressing BKV agnoprotein (Figure 4A
and B). These results suggests that BKV agnoprotein negatively
influences the export of VSVG-EGFP to the plasma membrane.
Discussion
In this study, we have identified the first cellular interaction
partner for BKV agnoprotein. The interaction between this viral
protein and a-SNAP has been shown by several methods including
GST-pull downs, co-immunoprecipitation in vitro and from cell
lysates with ectopic or endogenous levels of the proteins. We have
also shown that the proteins can co-localize within the cells.
Moreover, we found that the amino acids 1–37 of agnoprotein are
predominantly involved in the interaction with a-SNAP. Finally,
we demonstrated that expression of BKV agnoprotein negatively
influences the secretory pathway by blocking protein export within
the cell, as evaluated by the VSVG-EGFP reporter.
So far, few interaction partners have been identified for JCV
agnoprotein and none for BKV agnoprotein. Although, BKV
agnoprotein pulled down protein(s) with molecular masses of
approximately 50, 75 and 100 kD from BKV-infected HUV-EC-
C cells [26], the identity of these proteins remains unknown. Yeast
two-hybrid assays have yielded two interaction partners for JCV
agnoprotein. The highly conserved N-terminal 24 amino acids of
JCV agnoprotein was used as bait in human embryonic kidney
293 cells and yielded HP1-a which was found to be involved in
nuclear egress of viral particles [24]. Our yeast two-hybrid screen
did not yield HP1-a as an interaction partner to BKV
agnoprotein, however this may be due to various sources and
quality of the cDNA libraries. Another yeast two-hybrid screen
using full-length JCV agnoprotein as bait in a human brain cDNA
library resulted in the discovery of FEZ-1 as a brain-specific
partner for JCV agnoprotein [37]. Our yeast two-hybrid screen
using two different human libraries identified 6 new putative
partners not previously identified as partners for BKV, JCV or
SV40 agnoprotein. The cellular interaction partner(s) of agnopro-
tein may therefore depend on the type of virus, cell line and
perhaps also the concentration of agnoprotein as well as post-
translational modifications of agnoprotein and/or its putative
partner.
BKV agnoprotein has previously been found to co-localize with
lipid droplets [25]. The proteome of lipid droplets includes the
SNAREs SNAP23, syntaxin-5 and VAMP4 as well as NSF and a-
SNAP [39,40]. Here we describe that BKV agnoprotein interacts
with a-SNAP, which therefore could be the direct interaction
partner localized on the lipid droplets. Interestingly, fusion of lipid
droplets required a-SNAP and SNAREs [38], and these proteins,
present on vesicles and target compartments, ensure appropriate
fusion and subsequent disassembly [27,28]. As overexpression of
BKV agnoprotein negatively influences the transport of VSVG-
EGFP (Figure 4), it is possible that the presence of BKV
agnoprotein may impair the disassembly process through compe-
tition with NSF for binding to a-SNAP. Such a reduction in
disassembly would limit the availability of SNAREs, thereby
causing the inhibition of secretion or fusion of lipid droplets.
Agnoprotein is highly conserved among SV40, JCV and BKV,
especially within the 35–40 amino acids at the N-terminal part
[18]. Interestingly, agnopeptide 1–37 and GST-agnoprotein-
stop38 could both specifically interact with a-SNAP. Given the
sequence conservation in the N-terminal region of agnoprotein,
our data suggest that agnoprotein of JCV and SV40 may also
interact with a-SNAP and that the inhibitory mechanism may be
conserved as well.
BKV agnoprotein has been found to be phosphorylated in vivo
[20,26], and Ser-7, Ser-11 and Thr-21 were identified as phospho-
acceptor sites for PKC and PKD in vitro [20]. Circular dichroism
results of BKV agnoprotein and variants where Ser-11 was
mutated into alanine or aspartate suggest no major differences in
secondary structure (results not shown). Moreover, BKV agno-
protein mutants where Ser-11 or Ser-7/Ser-11/Thr-21 was
replaced by non-phosphorylatable alanine could still interact with
a-SNAP, as evaluated by co-immunoprecipitation of cell lysates
ectopically expressing these proteins (results not shown). These
results could indicate that the interaction between a-SNAP and
BKV agnoprotein is not regulated by phosphorylation at least not
by these phospho-acceptor sites combinations. a-SNAP may also
be regulated by phosphorylation [40,41], however, we have not
tested whether phosphorylation of a-SNAP is required for its
interaction with agnoprotein.
Several hypotheses could be made for the functional conse-
quence(s) of the interaction between agnoprotein and a-SNAP.
Firstly, agnoprotein may inhibit secretion and thereby interfere
with cell membrane integrity. JCV agnoprotein has been found to
follow an exocytic route from ER to plasma membrane, where it
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Figure 4. BKV agnoprotein negatively influences the transport of VSVG-EGFP. (A) HEK293 cells were transfected with VSVG-EGFP(ts045)
and RcCMV or RcCMV-agnoprotein and incubated at 40uC overnight. The cells were transferred to 32uC, fixed and immunostained against BKV
agnoprotein after various time intervals (0, 15 minutes, 1 h, 3 h and 5 h). The subcellular localization of VSVG-EGFP (green) in absence or presence of
BKV agnoprotein (red) was evaluated by confocal microscopy. (B) Enlargement of HEK293 cells transfected with VSVG-EGFP(ts045) and RcCMV or
RcCMV-agnoprotein and treated as in A. The cells were fixed and immunostained after 5 hours, and evaluated by confocal microscopy.
doi:10.1371/journal.pone.0024489.g004
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can function as viroporin [22]. By its interaction with a-SNAP and
its ability to interfere with secretion, agnoprotein may regulate the
formation of viroporins. Secondly, agnoprotein may negatively
influence secretion as a strategy for immune evasion. Cells
continuously degrade and present peptides via major histocom-
patibility complex I (MHC) molecules. The assembly of MHC I
and the antigenic peptide occurs in the ER, and the complexes are
transported to the cell surface by the constitutive secretory
pathway. At the cell surface, MHC I presents antigenic peptides
to cytotoxic T cells which results in destruction of infected cells
[42,43]. Several viruses interfere with the antigen presentation
pathway. Some viruses interfere with proteasomal processing of
antigenic peptides within the cytosol, while other viruses interfere
with peptide transport across the lumen of the ER or with the
retention, dislocation and destruction of MHC I in the ER and
early secretory compartments [44]. Another strategy used by
certain Herpesvirus subfamilies is to increase endocytosis and
subsequent degradation of MHC class I molecules from the
membrane ([45] and references therein), while poliovirus chooses
to inhibit the secretory pathway by means of viral proteins 2B or
3A, where the latter exhibits a stronger effect and is specific for
ER-to-Golgi traffic [46–48]. Alternatively, an agnoprotein-medi-
ated inhibition of the secretory pathway may reduce the secretion
of cytokines and/or a- and b-interferons. This strategy is used by
poliovirus where protein 3A limits IL-6, IL-8 and b-interferon
secretion during viral infection [47]. Another purpose of
agnoprotein to perturb the secretory pathway through targeting
a-SNAP could be to prevent premature release of incomplete
virions. In the initial stage of the late phase, agnoprotein is
abundantly expressed, and this may inhibit secretion of capsid
proteins and viral DNA that are incompletely assembled into
infectious virions. Later, when agnoprotein expression decreases,
the inhibition of secretion is abrogated and completely maturated
virus particles can be released.
Agnoprotein is a small auxiliary protein, which has been found to
influence viral transcription, as well as viral assembly, viral release
and propagation [18]. The viral protein is expressed late in the viral
life cycle, and the function may depend on the concentration and
post-transcriptional regulation of itself, as well as its interaction
partner. The interference with secretion may therefore vary during
viral propagation, but this remains to be investigated.
In summary, we have identified the first cellular interaction
partner of BKV agnoprotein, and we have shown that the
interaction between a-SNAP and agnoprotein occurs in BKV
infected cells. The N-terminal 1–37 amino acids are involved in
the interaction, which may suggest that also JCV and SV40
agnoprotein can interact with a-SNAP. Finally, we show that
BKV agnoprotein negatively interferes with secretion.
Supporting Information
Figure S1 Vero cells were transfected with expression
plasmids encoding BKV agnoprotein (200 ng) and a-
SNAP (200 ng). The cells were fixated and immunostained
against BKV agnoprotein and a-SNAP. The cell nuclei were
visualized by DRAQ5 staining. Arrows indicate co-localization of
BKV agnoprotein and a-SNAP.
(TIF)
Figure S2 Peptide 38–66 is detected by immunoblot.
50 ng, 250 ng, and 500 ng peptide 38–66 were separated on SDS
PAGE (NuPAGE, Invitrogen), followed by immunoblot using
antibody against agnoprotein as primary antibody, and HRP-
conjugated goat anti rabbit secondary antibody.
(TIF)
Acknowledgments
We thank Drs. Mitsuo Tagoya and Kuy-Jin Park for kindly providing
plasmids used in this study. We acknowledge Conny Tu¨mmler for excellent
technical help.
Author Contributions
Conceived and designed the experiments: MJ UM. Performed the
experiments: MW MJ NG MD. Analyzed the data: MJ MW NG MD
AS UM. Wrote the paper: MJ UM AS NG MW MD.
References
1. Eash S, Manley K, Gasparovic M, Querbes W, Atwood WJ (2006) The human
polyomaviruses. Cell Mol Life Sci 63: 865–876.
2. Moens U, Van Ghelue M, Johannessen M (2007) Human Polyomavirus:
Molecular Mechanisms for transformation and their association with cancers.
In: Elliot I, ed. New Research on oncogenic viruses New York Nova Science
Publishers. pp 1–63.
3. Kean JM, Rao S, Wang M, Garcea RL (2009) Seroepidemiology of human
polyomaviruses. PLoS Pathog 5: e1000363.
4. Patel NC, Vilchez RA, Killen DE, Zanwar P, Sroller V, et al. (2008) Detection
of polyomavirus SV40 in tonsils from immunocompetent children. J Clin Virol
43: 66–72.
5. Delbue S, Tremolada S, Branchetti E, Elia F, Gualco E, et al. (2008) First
identification and molecular characterization of lymphotropic polyomavirus in
peripheral blood from patients with leukoencephalopathies. J Clin Microbiol 46:
2461–2462.
6. Allander T, Andreasson K, Gupta S, Bjerkner A, Bogdanovic G, et al. (2007)
Identification of a third human polyomavirus. J Virol 81: 4130–4136.
7. Gaynor AM, Nissen MD, Whiley DM, Mackay IM, Lambert SB, et al. (2007)
Identification of a novel polyomavirus from patients with acute respiratory tract
infections. PLoS Pathog 3: e64.
8. Feng H, Shuda M, Chang Y, Moore PS (2008) Clonal Integration of a
Polyomavirus in Human Merkel Cell Carcinoma. Science 319: 1096–1100.
9. Schowalter RM, Pastrana DV, Pumphrey KA, Moyer AL, Buck CB (2010)
Merkel cell polyomavirus and two previously unknown polyomaviruses are
chronically shed from human skin. Cell Host Microbe 7: 509–515.
10. van der Meijden E, Janssens RW, Lauber C, Bouwes Bavinck JN,
Gorbalenya AE, et al. (2010) Discovery of a new human polyomavirus
associated with trichodysplasia spinulosa in an immunocompromized patient.
PLoS Pathog 6: e1001024.
11. Scuda N, Hofmann J, Calvignac-Spencer S, Ruprecht K, Liman P, et al. (2011)
A novel human polyomavirus closely related to the African green monkey-
derived lymphotropic polyomavirus (LPV). J Virol 85: 4586–4590.
12. Hirsch H (2005) BK virus: opportunity makes a pathogen. Clin Infect Dis 41:
354–360.
13. Rinaldo CH, Hirsch HH (2007) Antivirals for the treatment of polyomavirus BK
replication. Expert Rev Anti Infect Ther 5: 105–115.
14. Jiang M, Abend JR, Johnson SF, Imperiale MJ (2008) The role of
polyomaviruses in human disease. Virology 384: 266–273.
15. Viscidi RP, Shah KV (2008) Cancer. A skin cancer virus? Science 319:
1049–1050.
16. Moens U, Rekvig OP (2001) Molecular biology of BK virus and clinical and
basic aspects of BK virus renal infection. In: Khalili K, Stoner GL, eds. Human
polyomaviruses Molecular and clinical perspectives Wiley&Sons, Inc. New York.
pp 359–408.
17. Daniels R, Sadowicz D, Hebert DN (2007) A Very Late Viral Protein Triggers
the Lytic Release of SV40. PLoS Pathog 3: e98.
18. Khalili K, White MK, Sawa H, Nagashima K, Safak M (2005) The agnoprotein
of polyomaviruses: a multifunctional auxiliary protein. J Cell Physiol 204: 1–7.
19. Sariyer IK, Akan I, Palermo V, Gordon J, Khalili K, et al. (2006)
Phosphorylation mutants of JC virus agnoprotein are unable to sustain the
viral infection cycle. J Virol 80: 3893–3903.
20. Johannessen M, Myhre MR, Dragset M, Tu¨mmler C, Moens U (2008)
Phosphorylation of human polyomavirus BK agnoprotein at Ser-11 is mediated
by PKC and has an important regulative function. Virology 379: 97–109.
21. Resnick J, Shenk T (1986) Simian virus 40 agnoprotein facilitates normal
nuclear location of the major capsid polypeptide and cell-to-cell spread of virus.
J Virol 60: 1098–1106.
22. Suzuki T, Orba Y, Okada Y, Sunden Y, Kimura T, et al. (2010) The human
polyoma JC virus agnoprotein acts as a viroporin. PLoS Pathog 6: e1000801.
BK Virus Agnoprotein May Interfere with Secretion
PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e24489
23. Safak M, Barrucco R, Darbinyan A, Okada Y, Nagashima K, et al. (2001)
Interaction of JC virus agno protein with T antigen modulates transcription and
replication of the viral genome in glial cells. J Virol 75: 1476–1486.
24. Okada Y, Suzuki T, Sunden Y, Orba Y, Kose S, et al. (2005) Dissociation of
heterochromatin protein 1 from lamin B receptor induced by human
polyomavirus agnoprotein: role in nuclear egress of viral particles. EMBO
Rep 6: 452–457.
25. Unterstab G, Gosert R, Leuenberger D, Lorentz P, Rinaldo CH, et al. (2010)
The polyomavirus BK agnoprotein co-localizes with lipid droplets. Virology 399:
322–331.
26. Rinaldo CH, Traavik T, Hey A (1998) The agnogene of the human
polyomavirus BK is expressed. J Virol 72: 6233–6236.
27. Zhao C, Slevin JT, Whiteheart SW (2007) Cellular functions of NSF: not just
SNAPs and SNAREs. FEBS Lett 581: 2140–2149.
28. Jahn R, Scheller RH (2006) SNAREs–engines for membrane fusion. Nat Rev
Mol Cell Biol 7: 631–643.
29. Hey AW, Johnsen JI, Johansen B, Traavik T (1994) A two fusion partner system
for raising antibodies against small immunogens expressed in bacteria.
J Immunol Methods 173: 149–156.
30. Grinde B, Gayorfar M, Rinaldo CH (2007) Impact of a polyomavirus (BKV)
infection on mRNA expression in human endothelial cells. Virus Res 123:
86–94.
31. Nakajima K, Hirose H, Taniguchi M, Kurashina H, Arasaki K, et al. (2004)
Involvement of BNIP1 in apoptosis and endoplasmic reticulum membrane
fusion. EMBO J 23: 3216–3226.
32. Presley JF, Cole NB, Schroer TA, Hirschberg K, Zaal KJ, et al. (1997) ER-to-
Golgi transport visualized in living cells. Nature 389: 81–85.
33. Park KJ, Gaynor YT, Kwak J (2003) Heat shock protein 27 association with the
I kappa B kinase complex regulates tumor necrosis factor alpha-induced NF-
kappa B activation. J Biol Chem 278: 35272–35278.
34. Johannessen M, Delghandi MP, Rykx A, Dragset M, Vandenheede JR, et al.
(2007) Protein kinase D induces transcription through direct phosphorylation of
the cAMP-response element-binding protein. J Biol Chem 282: 14777–14787.
35. Einarson MB (2004) Detection of protein-protein interactions using the GST
fusion protein pull-down technique. Nature methods 1: 275–276.
36. Rinaldo CH, Myhre MR, Alstad H, Nilssen O, Traavik T (2003) Human
polyomavirus BK (BKV) transiently transforms and persistently infects cultured
osteosarcoma cells. Virus Res 93: 181–187.
37. Suzuki T, Okada Y, Semba S, Orba Y, Yamanouchi S, et al. (2005)
Identification of FEZ1 as a protein that interacts with JC virus agnoprotein
and microtubules: role of agnoprotein-induced dissociation of FEZ1 from
microtubules in viral propagation. J Biol Chem 280: 24948–24956.
38. Bostrom P, Andersson L, Rutberg M, Perman J, Lidberg U, et al. (2007)
SNARE proteins mediate fusion between cytosolic lipid droplets and are
implicated in insulin sensitivity. Nat Cell Biol 9: 1286–1293.
39. Liu P, Ying Y, Zhao Y, Mundy DI, Zhu M, Anderson RG (2004) Chinese
hamster ovary K2 cell lipid droplets appear to be metabolic organelles involved
in membrane traffic. J Biol Chem 279: 3787–3792.
40. Hirling H, Scheller RH (1996) Phosphorylation of synaptic vesicle proteins:
modulation of the alpha SNAP interaction with the core complex. Proc Natl
Acad Sci 93: 11945–11949.
41. Matveeva EA, Whiteheart SW, Vanaman TC, Slevin JT (2001) Phosphorylation
of the N-ethylmaleimide-sensitive factor is associated with depolarization-
dependent neurotransmitter release from synaptosomes. J Biol Chem 276:
12174–12181.
42. Donaldson JG, Williams DB (2009) Intracellular assembly and trafficking of
MHC class I molecules. Traffic 10: 1745–1752.
43. Pamer E, Cresswell P (1998) Mechanisms of MHC class I–restricted antigen
processing. Annu Rev Immunol 16: 323–358.
44. Hansen TH, Bouvier M (2009) MHC class I antigen presentation: learning from
viral evasion strategies. Nat Rev Immunol 9: 503–513.
45. Blagoveshchenskaya AD, Thomas L, Feliciangeli SF, Hung CH, Thomas G
(2002) HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated
ARF6 endocytic pathway. Cell 111: 853–866.
46. Deitz SB, Dodd DA, Cooper S, Parham P, Kirkegaard K (2000) MHC I-
dependent antigen presentation is inhibited by poliovirus protein 3A. Proc Natl
Acad Sci 97: 13790–13795.
47. Dodd DA, Giddings TH, Jr., Kirkegaard K (2001) Poliovirus 3A protein limits
interleukin-6 (IL-6), IL-8, and beta interferon secretion during viral infection.
Proc Natl Acad Sci 75: 8158–8165.
48. Doedens JR, Kirkegaard K (1995) Inhibition of cellular protein secretion by
poliovirus proteins 2B and 3A. EMBO J 14: 894–907.
BK Virus Agnoprotein May Interfere with Secretion
PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e24489
